Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Emery

Showing results (521-530 of 586) with videos related to

Pageof 59
Sort By:
Annals of the Rheumatic Diseases|July 3, 2008
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockadeJ S Smolen, C Han, D M F M van der Heijde, et al.
Fetal Diagnosis and Therapy|May 23, 2017
Fetal Treatment 2017: The Evolution of Fetal Therapy Centers - A Joint Opinion from the International Fetal Medicine and Surgical Society (IFMSS) and the North American Fetal Therapy Network (NAFTNet)Anita J Moon-Grady, Ahmet Baschat, Darrell Cass, et al.
Annals of the Rheumatic Diseases|December 19, 2007
A novel TNFRSF1A splice mutation associated with increased nuclear factor kappaB (NF-kappaB) transcription factor activation in patients with tumour necrosis factor receptor associated periodic syndrome (TRAPS)S M Churchman, L D Church, S Savic, et al.
Annals of the Rheumatic Diseases|January 21, 2014
Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness studyP Emery, J E Gottenberg, A Rubbert-Roth, et al.
Annals of the Rheumatic Diseases|September 4, 2004
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitisA Calin, B A C Dijkmans, P Emery, et al.
Annals of the Rheumatic Diseases|December 3, 2003
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II studyL B A van de Putte, R Rau, F C Breedveld, et al.
Rheumatology (Oxford, England)|September 29, 1999
Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2P Brooks, P Emery, J F Evans, et al.
Annals of the Rheumatic Diseases|November 21, 2007
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007D E Furst, F C Breedveld, J R Kalden, et al.
Obstetrics and Gynecology|January 17, 2025
Mode of Delivery and Subsequent Motor Function in Children With Myelomeningocele Without In Utero RepairAnna Palatnik, Amy Y Pan, Stephen P Emery, et al.
Annals of the Rheumatic Diseases|April 15, 2004
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failedL B A van de Putte, C Atkins, M Malaise, et al.
Pageof 59

Showing results (521-530 of 586) with videos related to

Sort By:
Pageof 59
Annals of the Rheumatic Diseases|July 3, 2008
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockadeJ S Smolen, C Han, D M F M van der Heijde, et al.
Fetal Diagnosis and Therapy|May 23, 2017
Fetal Treatment 2017: The Evolution of Fetal Therapy Centers - A Joint Opinion from the International Fetal Medicine and Surgical Society (IFMSS) and the North American Fetal Therapy Network (NAFTNet)Anita J Moon-Grady, Ahmet Baschat, Darrell Cass, et al.
Annals of the Rheumatic Diseases|December 19, 2007
A novel TNFRSF1A splice mutation associated with increased nuclear factor kappaB (NF-kappaB) transcription factor activation in patients with tumour necrosis factor receptor associated periodic syndrome (TRAPS)S M Churchman, L D Church, S Savic, et al.
Annals of the Rheumatic Diseases|January 21, 2014
Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness studyP Emery, J E Gottenberg, A Rubbert-Roth, et al.
Annals of the Rheumatic Diseases|September 4, 2004
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitisA Calin, B A C Dijkmans, P Emery, et al.
Annals of the Rheumatic Diseases|December 3, 2003
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II studyL B A van de Putte, R Rau, F C Breedveld, et al.
Rheumatology (Oxford, England)|September 29, 1999
Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2P Brooks, P Emery, J F Evans, et al.
Annals of the Rheumatic Diseases|November 21, 2007
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007D E Furst, F C Breedveld, J R Kalden, et al.
Obstetrics and Gynecology|January 17, 2025
Mode of Delivery and Subsequent Motor Function in Children With Myelomeningocele Without In Utero RepairAnna Palatnik, Amy Y Pan, Stephen P Emery, et al.
Annals of the Rheumatic Diseases|April 15, 2004
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failedL B A van de Putte, C Atkins, M Malaise, et al.
Pageof 59